3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
3
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
75
Neoplasms
15
Neoplasm Metastasis
9
Advanced Breast Cancer
5
Neoplasms by Site
3
Breast Diseases
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Patient Compliance
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Recurrence
1
Quality of Life
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Bone Density
1
Arthralgia
1
Advanced Metastatic Breast Cancer
1
Interventions
exemestane
4
entinostat
4
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
pembrolizumab
1
ipatasertib
1
figitumumab
1
elacestrant
1
dactolisib
1
atezolizumab
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Lapatinib
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Diseases
×
Anastrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled